160 related articles for article (PubMed ID: 22229973)
21. Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials.
Mannuccio Mannucci P; Kyrle PA; Schulman S; Di Paola J; Schneppenheim R; Cox Gill J
Blood Transfus; 2013 Oct; 11(4):533-40. PubMed ID: 23736911
[TBL] [Abstract][Full Text] [Related]
22. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease.
Ver Elst KM; van Vliet HD; Kappers-Klunne MC; Leebeek FW
Thromb Haemost; 2004 Jul; 92(1):67-74. PubMed ID: 15213847
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
24. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
Dunkley S; Baker RI; Pidcock M; Price J; Seldon M; Smith M; Street A; Maher D; Barrese G; Stone C; Lloyd J
Haemophilia; 2010 Jul; 16(4):615-24. PubMed ID: 20331755
[TBL] [Abstract][Full Text] [Related]
25. Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data.
Kouides P; Wawra-Hehenberger K; Sajan A; Mead H; Simon T
Transfusion; 2017 Oct; 57(10):2390-2403. PubMed ID: 28691218
[TBL] [Abstract][Full Text] [Related]
26. Acquired Von Willebrand syndrome is an early-onset problem in ventricular assist device patients.
Heilmann C; Geisen U; Beyersdorf F; Nakamura L; Trummer G; Berchtold-Herz M; Schlensak C; Zieger B
Eur J Cardiothorac Surg; 2011 Dec; 40(6):1328-33; discussion 1233. PubMed ID: 21515067
[TBL] [Abstract][Full Text] [Related]
27. Acquired Von Willebrand syndrome in patients on long-term support with HeartMate II.
Heilmann C; Trummer G; Beyersdorf F; Brehm K; Berchtold-Herz M; Schelling J; Geisen U; Zieger B
Eur J Cardiothorac Surg; 2017 Mar; 51(3):587-590. PubMed ID: 28082469
[TBL] [Abstract][Full Text] [Related]
28. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease.
Turecek PL; Gritsch H; Pichler L; Auer W; Fischer B; Mitterer A; Mundt W; Schlokat U; Dorner F; Brinkman HJ; van Mourik JA; Schwarz HP
Blood; 1997 Nov; 90(9):3555-67. PubMed ID: 9345039
[TBL] [Abstract][Full Text] [Related]
29. Review of von Willebrand Disease and Acquired von Willebrand Syndrome for Patients Undergoing Cardiac Surgery.
Berger J; Schwartz J; Ramachandran S; Leff JD
J Cardiothorac Vasc Anesth; 2019 Dec; 33(12):3446-3457. PubMed ID: 31570241
[No Abstract] [Full Text] [Related]
30. Acquired von Willebrand disease in monoclonal gammapathies: effectiveness of high-dose intravenous gamma globulin.
Michiels JJ; van Vliet HH
Clin Appl Thromb Hemost; 1999 Jul; 5(3):152-7. PubMed ID: 10726000
[TBL] [Abstract][Full Text] [Related]
31. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
32. Establishing a method for in vitro investigation of mechanical parameters causing acquired von Willebrand syndrome in ventricular assist devices.
Egger C; Maas J; Hufen T; Schmitz-Rode T; Steinseifer U
Artif Organs; 2013 Sep; 37(9):833-9. PubMed ID: 23834027
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.
Batty P; Chen YH; Bowles L; Hart DP; Platton S; Pasi KJ
Haemophilia; 2014 Nov; 20(6):846-53. PubMed ID: 25102895
[TBL] [Abstract][Full Text] [Related]
34. Acquired von Willebrand syndrome in a child following Berlin Heart EXCOR Pediatric Ventricular Assist Device implantation: case report and concise literature review.
Costello JP; Diab YA; Philippe-Auguste M; Jones MB; Shankar V; Friedman KD; Nath DS
World J Pediatr Congenit Heart Surg; 2014 Oct; 5(4):592-8. PubMed ID: 25324261
[TBL] [Abstract][Full Text] [Related]
35. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
36. Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease.
Favaloro EJ; Thom J; Patterson D; Just S; Baccala M; Dixon T; Meiring M; Koutts J; Rowell J; Baker R
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):475-83. PubMed ID: 19584715
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
[TBL] [Abstract][Full Text] [Related]
38. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).
Lissitchkov TJ; Buevich E; Kuliczkowski K; Stasyshyn O; Cerqueira MH; Klukowska A; Joch C; Seifert W
Blood Coagul Fibrinolysis; 2017 Mar; 28(2):152-162. PubMed ID: 27203734
[TBL] [Abstract][Full Text] [Related]
40. Bleeding management of uterine conization using a pasteurized FVIII/VWF Concentrate in a woman affected by type 2A von willebrand disease.
Lapecorella M; Napoletano M; Mariani G; Mascaretti G; Colageo E
Clin Appl Thromb Hemost; 2009; 15(2):245-6. PubMed ID: 18160560
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
